{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:10:40Z","timestamp":1788844240370,"version":"build-2803163510"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The diagnosis of high-grade neuroendocrine carcinoma may be challenging when conventional neuroendocrine markers show limited or discordant expression. POU2F3 is associated with a neuroendocrine-low subset of small cell carcinoma, but its incremental contribution in routine diagnostic practice remains incompletely defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the adjunctive diagnostic utility of POU2F3 in predominantly pulmonary high-grade neuroendocrine carcinomas, particularly in cases with limited or discordant conventional marker expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective case-control study included 140 neuroendocrine carcinomas and 100 poorly differentiated non-neuroendocrine controls. POU2F3 expression was assessed in biopsy and resection specimens and analyzed according to histological subtype, chromogranin A status, marker-discordant status, and diagnostic-panel interpretation. Diagnostic performance was reported with 95% confidence intervals, and paired changes after incorporation of POU2F3 were evaluated using the exact McNemar test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      POU2F3 was positive in 28 of 140 neuroendocrine carcinomas and 2 of 100 controls. Positivity was more frequent in chromogranin A-negative\/low than in chromogranin A-positive neuroendocrine carcinomas (34.5% vs. 10.6%; odds ratio, 4.46; 95% confidence interval, 1.84\u201310.82;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001). Positivity was identical in biopsy and resection specimens (20.0% vs. 20.0%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20091.000). POU2F3 alone showed 20.0% sensitivity and 98.0% specificity. Incorporation of POU2F3 increased panel sensitivity from 80.7% to 91.4% and accuracy from 87.1% to 93.3%, while specificity remained 96.0% (exact McNemar\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>POU2F3 has limited stand-alone sensitivity but provides incremental diagnostic support in selected neuroendocrine carcinomas with limited or discordant conventional marker expression. It should be used selectively and interpreted together with morphology and established neuroendocrine markers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1886172","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:26:49Z","timestamp":1788841609000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjunctive diagnostic utility of POU2F3 in predominantly pulmonary high-grade neuroendocrine carcinomas with limited or discordant conventional marker expression: a case-control study"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiangxiang","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Pathology, Jiashan Hospital of Traditional Chinese Medicine","place":["Jiaxing City, Zhejiang Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Wuxi Branch of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Wuxi, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12885-023-10797-3","article-title":"Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1097\/JTO.0000000000000589","article-title":"Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy","volume":"10","author":"Fasano","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/his.15058","article-title":"Updates on lung neuroendocrine neoplasm classification","volume":"84","author":"Vocino Trucco","year":"2024","journal-title":"Histopathology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.31557\/apjcb.2021.6.1.49-55","article-title":"Neuroendocrine differentiation in non-small cell lung cancer and its relation to different pathologic features: an immunohistochemical study","volume":"6","author":"El-Hussien","year":"2021","journal-title":"Asian Pacific J Cancer Biol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41379-018-0122-7","article-title":"Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections","volume":"32","author":"Mukhopadhyay","year":"2019","journal-title":"Mod Pathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.3892\/ol.2020.11336","article-title":"Secretagogin, a marker for neuroendocrine cells, is more sensitive and specific in large cell neuroendocrine carcinoma compared with the markers CD56, CgA, syn and napsin A","volume":"19","author":"Dong","year":"2020","journal-title":"Oncol Lett"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3390\/jcm11051461","article-title":"Large cell neuroendocrine carcinoma of the lung: current understanding and challenges","volume":"11","author":"Andrini","year":"2022","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC Subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"73745","DOI":"10.18632\/oncotarget.20572","article-title":"Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer","volume":"8","author":"McColl","year":"2017","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jtho.2022.06.004","article-title":"POU2F3 In SCLC: clinicopathologic and genomic analysis with a focus on its diagnostic utility in neuroendocrine-low SCLC","volume":"17","author":"Baine","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1101\/gad.314815.118","article-title":"POU2F3 Is a master regulator of a tuft cell-like variant of small cell lung cancer","volume":"32","author":"Huang","year":"2018","journal-title":"Genes Dev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1038\/s41467-024-46492-5","article-title":"A SWI\/SNF-dependent transcriptional regulation mediated by POU2AF2\/C11orf53 at enhancer","volume":"15","author":"Szczepanski","year":"2024","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","first-page":"108033","DOI":"10.1016\/j.lungcan.2024.108033","article-title":"The molecular subtypes of small cell lung cancer defined by key transcription factors and their clinical significance","volume":"198","author":"Yu","year":"2024","journal-title":"Lung Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"779276","DOI":"10.3389\/fonc.2022.779276","article-title":"Prognostic implications of molecular subtypes in primary small cell lung cancer and their correlation with cancer immunity. Original research","volume":"12","author":"Qi","year":"2022","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1097\/PAS.0000000000002081","article-title":"POU2F3: a sensitive and specific diagnostic marker for neuroendocrine-low\/negative small cell lung cancer","volume":"47","author":"Wang","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/PAS.0000000000002145","article-title":"POU2F3-Expressing Small cell lung carcinoma and large cell neuroendocrine carcinoma show morphologic and phenotypic overlap","volume":"48","author":"Jimbo","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00428-020-03015-z","article-title":"Morphologic and molecular classification of lung neuroendocrine neoplasms","volume":"478","author":"Metovic","year":"2021","journal-title":"Virchows Arch"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.21037\/tlcr-20-269","article-title":"New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts","volume":"9","author":"Lantuejoul","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001977","article-title":"Molecular classification of extrapulmonary neuroendocrine carcinomas with emphasis on POU2F3-positive tuft cell carcinoma","volume":"47","author":"Koh","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101113","DOI":"10.1016\/j.ctarc.2026.101113","article-title":"Characterization of POU2F3-expressing large cell neuroendocrine carcinoma of the lung: a comprehensive analysis of morphology, immunohistochemistry, and genomic alterations","volume":"46","author":"Matsuoka","year":"2026","journal-title":"Cancer Treat Res Commun"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100557","DOI":"10.1016\/j.modpat.2024.100557","article-title":"Differential NEUROD1, ASCL1, and POU2F3 expression defines molecular subsets of bladder small cell\/neuroendocrine carcinoma with prognostic implications","volume":"37","author":"Akbulut","year":"2024","journal-title":"Mod Pathol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.ccell.2024.06.012","article-title":"Mammalian SWI\/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer","volume":"42","author":"Duplaquet","year":"2024","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.ccell.2024.06.006","article-title":"Targeting the mSWI\/SNF complex in POU2F-POU2AF transcription factor-driven malignancies","volume":"42","author":"He","year":"2024","journal-title":"Cancer Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00428-024-03754-3","article-title":"Heterogeneity of molecular subtyping and therapy-related marker expression in primary tumors and paired lymph node metastases of small cell lung cancer","volume":"486","author":"Zhu","year":"2025","journal-title":"Virchows Arch"},{"key":"B25","doi-asserted-by":"publisher","first-page":"S368","DOI":"10.1016\/j.jtho.2023.09.649","article-title":"P2.13-05 spatiotemporal heterogeneity of transcription factor-based subtype assignment in small cell lung carcinoma","volume":"18","author":"Meador","year":"2023","journal-title":"J Thorac Oncol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1886172\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:26:50Z","timestamp":1788841610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1886172\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":25,"alternative-id":["10.3389\/fmed.2026.1886172"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1886172","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1886172"}}